Alterations in the p53 pathway and their association with radio- and chemosensitivity in head and neck squamous cell carcinoma

Oral Oncology

Volumn 44, Issue 12, 2008, Pages 1100-1109

  Hoffmann, Thomas K ^a   Sonkoly, Eniko ^a   Hauser, Ulrich ^a   van Lierop, Anke ^a   Whiteside, Theresa L ^b   Klussmann, Jens Peter ^c   Hafner, Dieter ^a   Schuler, Patrick ^a   Friebe Hoffmann, Ulrike ^a   Scheckenbach, Kathrin ^a   Erjala, Kaisa ^d   Grénman, Reidar ^d   Schipper, Jörg ^a   Bier, Henning ^e   Balz, Vera ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF COLOGNE   (Germany)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Chemosensitivity; HDM 2 MDM 2; Head and neck cancer; Human papillomavirus; p14ARF; p53 pathway; Radiosensitivity

Indexed keywords

CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; ONCOPROTEIN; PROTEIN MDM2; PROTEIN P53;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CHEMOSENSITIVITY; DISEASE ASSOCIATION; DRUG SENSITIVITY; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IC 50; IMMUNOHISTOCHEMISTRY; ONCOGENE; PRIORITY JOURNAL; PROTEIN ANALYSIS; RADIOSENSITIVITY; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; WILD TYPE;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CISPLATIN; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; ONCOGENE PROTEINS, VIRAL; RADIATION TOLERANCE; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 56249112965     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2008.02.006     Document Type: Article

References (46)

1. Genden E.M., Ferlito A., Bradley P.J., Rinaldo A., and Scully C. Neck disease and distant metastases. Oral Oncol 39 3 (2003) 207-212
2. Mao L., Hong W.K., and Papadimitrakopoulou V.A. Focus on head and neck cancer. Cancer Cell 5 4 (2004) 311-316
3. Hollstein M., Sidransky D., Vogelstein B., and Harris C.C. p53 mutations in human cancers. Science 253 5015 (1991) 49-53
4. Royds J.A., and Iacopetta B. p53 and disease: when the guardian angel fails. Cell Death Differ (2006)
5. Brennan J.A., Boyle J.O., Koch W.M., Goodman S.N., Hruban R.H., Eby Y.J., et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. New Engl J Med 332 11 (1995) 712-717
6. Kropveld A., Rozemuller E.H., Leppers F.G., Scheidel K.C., de Weger R.A., Koole R., et al. Sequencing analysis of RNA and DNA of exons 1 through 11 shows p53 gene alterations to be present in almost 100% of head and neck squamous cell cancers. Lab Invest 79 3 (1999) 347-353
7. Balz V., Scheckenbach K., Gotte K., Bockmuhl U., Petersen I., and Bier H. Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res 63 6 (2003) 1188-1191
8. Bossi G., Lapi E., Strano S., Rinaldo C., Blandino G., and Sacchi A. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene 25 2 (2006) 304-309
9. Harris S.L., and Levine A.J. The p53 pathway: positive and negative feedback loops. Oncogene 24 17 (2005) 2899-2908
10. Issaeva N., Bozko P., Enge M., Protopopova M., Verhoef L.G., Masucci M., et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 10 12 (2004) 1321-1328
11. Vanderborght A., Valckx A., Van Dun J., Grand-Perret T., De Schepper S., Vialard J., et al. Effect of an hdm-2 antagonist peptide inhibitor on cell cycle progression in p53-deficient H1299 human lung carcinoma cells. Oncogene (2006)
12. Bond G.L., Hu W., Bond E.E., Robins H., Lutzker S.G., Arva N.C., et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119 5 (2004) 591-602
13. Sharpless N.E. INK4a/ARF: a multifunctional tumor suppressor locus. Mutat Res 576 1-2 (2005) 22-38
14. Perez-Ordonez B., Beauchemin M., and Jordan R.C. Molecular biology of squamous cell carcinoma of the head and neck. J Clin Pathol 59 5 (2006) 445-453
15. Chen R., Aaltonen L.M., and Vaheri A. Human papillomavirus type 16 in head and neck carcinogenesis. Rev Med Virol 15 6 (2005) 351-363
16. Cuddihy A.R., and Bristow R.G. The p53 protein family and radiation sensitivity: yes or no?. Cancer Metast Rev 23 3-4 (2004) 237-257
17. Lothaire P., de Azambuja E., Dequanter D., Lalami Y., Sotiriou C., Andry G., et al. Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation. Head Neck 28 3 (2006) 256-269
18. Hauser U., Balz V., Carey T.E., Grenman R., Van Lierop A., Scheckenbach K., et al. Reliable detection of p53 aberrations in squamous cell carcinomas of the head and neck requires transcript analysis of the entire coding region. Head Neck 24 9 (2002) 868-873
19. Ballo H., Koldovsky P., Hoffmann T., Balz V., Hildebrandt B., Gerharz C.D., et al. Establishment and characterization of four cell lines derived from human head and neck squamous cell carcinomas for an autologous tumor-fibroblast in vitro model. Anticancer Res 19 5B (1999) 3827-3836
20. Lansford C., Grenman R., and Bier H. Head and neck cancers. In: Masters J., and Palsson B. (Eds). Human cell culture (1999), Kluwer, London 185-255
21. Klussmann J.P., Weissenborn S.J., Wieland U., Dries V., Kolligs J., Jungehuelsing M., et al. Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer 92 11 (2001) 2875-2884
22. Hoffmann T.K., Arsov C., Schirlau K., Bas M., Friebe-Hoffmann U., Klussmann J.P., et al. T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx. Int J Cancer 118 8 (2006) 1984-1991
23. Fanucchi M., and Khuri F.R. Chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck. Semin Oncol 31 6 (2004) 809-815
24. Bradford C.R., Zhu S., Ogawa H., Ogawa T., Ubell M., Narayan A., et al. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 25 8 (2003) 654-661
25. Mandic R., Schamberger C.J., Muller J.F., Geyer M., Zhu L., Carey T.E., et al. Reduced cisplatin sensitivity of head and neck squamous cell carcinoma cell lines correlates with mutations affecting the COOH-terminal nuclear localization signal of p53. Clin Cancer Res 11 19 Pt 1 (2005) 6845-6852
26. Pekkola-Heino K., Servomaa K., Kiuru A., and Grenman R. Sublethal damage repair capacity in carcinoma cell lines with p53 mutations. Head Neck 20 4 (1998) 298-303
27. El-Deiry W.S. The role of p53 in chemosensitivity and radiosensitivity. Oncogene 22 47 (2003) 7486-7495
28. Wrighton K.H., Prele C.M., Sunters A., and Yeudall W.A. Aberrant p53 alters DNA damage checkpoints in response to cisplatin: downregulation of CDK expression and activity. Int J Cancer 112 5 (2004) 760-770
29. Patel V., Ensley J.F., Gutkind J.S., and Yeudall W.A. Induction of apoptosis in head-and-neck squamous carcinoma cells by gamma-irradiation and bleomycin is p53-independent. Int J Cancer 88 5 (2000) 737-743
30. Zamble D.B., Jacks T., and Lippard S.J. p53-Dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells. Proc Natl Acad Sci USA 95 11 (1998) 6163-6168
31. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., and Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63 6 (1990) 1129-1136
32. Padilla L.A., Leung B.S., and Carson L.F. Evidence of an association between human papillomavirus and impaired chemotherapy-induced apoptosis in cervical cancer cells. Gynecol Oncol 85 1 (2002) 59-66
33. D'Souza G., Kreimer A.R., Viscidi R., Pawlita M., Fakhry C., Koch W.M., et al. Case-control study of human papillomavirus and oropharyngeal cancer. New Engl J Med 356 19 (2007) 1944-1956
34. Dai M., Clifford G.M., le Calvez F., Castellsague X., Snijders P.J., Pawlita M., et al. Human papillomavirus type 16 and TP53 mutation in oral cancer: matched analysis of the IARC multicenter study. Cancer Res 64 2 (2004) 468-471
35. Ferris R.L., Martinez I., Sirianni N., Wang J., Lopez-Albaitero A., Gollin S.M., et al. Human papillomavirus-16 associated squamous cell carcinoma of the head and neck (SCCHN): a natural disease model provides insights into viral carcinogenesis. Eur J Cancer 41 5 (2005) 807-815
36. Sacks P.G. Cell, tissue and organ culture as in vitro models to study the biology of squamous cell carcinomas of the head and neck. Cancer Metast Rev 15 1 (1996) 27-51
37. Shillitoe E.J., and Noonan S. Strength and specificity of different gene promoters in oral cancer cells. Oral Oncol 36 2 (2000) 214-220
38. Patel D., Incassati A., Wang N., and McCance D.J. Human papillomavirus type 16 E6 and E7 cause polyploidy in human keratinocytes and up-regulation of G2-M-phase proteins. Cancer Res 64 4 (2004) 1299-1306
39. Williams A.T., Sexton C.J., Sinclair A.L., Purdie K.J., Thomas M.S., Hanna N.A., et al. Retention of low copy number human papillomavirus DNA in cultured cutaneous and mucosal wart keratinocytes. J Gen Virol 75 Pt 3 (1994) 505-511
40. Hietanen S., Auvinen E., Grenman S., Lakkala T., Sajantila A., Klemi P., et al. Isolation of two keratinocyte cell lines derived from HPV-positive dysplastic vaginal lesions. Int J Cancer 52 3 (1992) 391-398
41. Atula S., Grenman R., Kujari H., and Syrjanen S. Detection of human papillomavirus (HPV) in laryngeal carcinoma cell lines provides evidence for a heterogeneic cell population. Eur J Cancer 35 5 (1999) 825-832
42. Raschke S., Balz V., Efferth T., Schulz W.A., and Florl A.R. Homozygous deletions of CDKN2A caused by alternative mechanisms in various human cancer cell lines. Gene Chromosome Canc 42 1 (2005) 58-67
43. Ishida E., Nakamura M., Ikuta M., Shimada K., Matsuyoshi S., Kirita T., et al. Promotor hypermethylation of p14ARF is a key alteration for progression of oral squamous cell carcinoma. Oral Oncol 41 6 (2005) 614-622
44. Lim K.P., Sharifah H., Lau S.H., Teo S.H., and Cheong S.C. Alterations of the p14ARF-p53-MDM2 pathway in oral squamous cell carcinoma: MDM2 overexpression is a common event. Oncol Rep 14 4 (2005) 963-968
45. Yanamoto S., Kawasaki G., Yoshitomi I., and Mizuno A. p53, mdm2, and p21 expression in oral squamous cell carcinomas: relationship with clinicopathologic factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 94 5 (2002) 593-600
46. Nenutil R., Smardova J., Pavlova S., Hanzelkova Z., Muller P., Fabian P., et al. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol 207 3 (2005) 251-259